Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity

Autor: Adrià Archilla-Ortega, Carla Domuro, Juan Martin-Liberal, Purificación Muñoz

Publikováno v: Journal of Experimental & Clinical Cancer Research, Vol 41, Iss 1, Pp 1-24 (2022)

Abstract Immunotherapy has emerged as a promising strategy for boosting antitumoral immunity. Blockade of immune checkpoints (ICs), which regulate the activity of cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells has proven clinical benefi

Externí odkaz: https://doaj.org/article/7d32ca9e6ba94ab49d287602e5776a86

Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity.

Autor: Archilla-Ortega, Adri๠(AUTHOR), Domuro, Carla¹ (AUTHOR), Martin-Liberal, Juan² (AUTHOR), Muñoz, Purificación¹ (AUTHOR) p.munoz@idibell.cat

Publikováno v: Journal of Experimental & Clinical Cancer Research (17569966). 2/14/2022, Vol. 41 Issue 1, p1-24. 24p.

Neuregulin 4 Downregulation Induces Insulin Resistance in 3T3-L1 Adipocytes through Inflammation and Autophagic Degradation of GLUT4 Vesicles

Autor: Marta Camps, Carla Blanco-Sinfreu, María Isabel Hernández-Alvarez, David Sebastián, M. Romero, Antonio Zorzano, Francisco Díaz-Sáez, Xavier Testar, Adrià Archilla-Ortega, Silvia Mora, Julián Aragonés, Anna Gumà, José Manuel Fernández-Real, Wifredo Ricart, José María Moreno-Navarrete

Publikováno v: International Journal of Molecular Sciences; Volume 22; Issue 23; Pages: 12960
International Journal of Molecular Sciences, Vol 22, Iss 12960, p 12960 (2021)
Dipòsit Digital de la UB
Universidad de Barcelona
International Journal of Molecular Sciences

The adipokine Neuregulin 4 (Nrg4) protects against obesity-induced insulin resistance. Here, we analyze how the downregulation of Nrg4 influences insulin action and the underlying mechanisms in adipocytes. Validated shRNA lentiviral vectors were used

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be2c9afa5816cede9f6b73444b85cb44

Modified UCN2 peptide treatment improves skeletal muscle mass and function in mouse models of obesity-induced insulin resistance

Autor: Thais de Castro Barbosa, Benjamin C. Yaden, Juleen R. Zierath, Jonathon A. B. Smith, Jorge Alsina-Fernandez, Melissa L. Borg, Julie Massart, Adrià Archilla‐Ortega, Håkan Karlsson, Johanna T. Lanner, Alexander E. Culver, Joseph T. Brozinick

Publikováno v: Journal of Cachexia, Sarcopenia and Muscle
Journal of Cachexia, Sarcopenia and Muscle, Vol 12, Iss 5, Pp 1232-1248 (2021)

Background Type 2 diabetes and obesity are often seen concurrently with skeletal muscle wasting, leading to further derangements in function and metabolism. Muscle wasting remains an unmet need for metabolic disease, and new approaches are warranted.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c12329748f40cdf86311c20d641aa33c
https://pubmed.ncbi.nlm.nih.gov/34342159